Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma
文献类型：期刊论文
| 作者 | Cao, Haiqiang1,2; Wang, Yixin1,2,3; He, Xinyu1,2; Zhang, Zhiwen1,2 ; Yin, Qi1,2; Chen, Yi1,2; Yu, Haijun1,2; Huang, Yongzhuo1,2; Chen, Lingli1,2; Xu, Minghua1,2
|
| 刊名 | MOLECULAR PHARMACEUTICS
 |
| 出版日期 | 2015-03 |
| 卷号 | 12期号:3页码:922-931 |
| 关键词 | sorafenib curcumin nanoparticles codelivery hepatocellular carcinoma |
| ISSN号 | 1543-8384 |
| DOI | 10.1021/mp500755j |
| 文献子类 | Article |
| 英文摘要 | Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Herein, we first reported the codelivery of sorafenib and curcumin by directed self-assembled nanoparticles (SCN) to enhance the therapeutic effect on HCC. SCN was formed by employing the hydrophobic interactions among the lipophilic structure in sorafenib, curcumin, and similar hydrophobic segments of polyethylene glycol derivative of vitamin E succinate (PEG-VES), which comprised uniform spherical particles with particle size of 84.97 +/- 6.03 nm. SCN presented superior effects over sorafenib, curcumin, and their physical mixture (Sora + Cur) on enhancing in vitro cytotoxicity and cell apoptosis in BEL-7402 cells and Hep G2 cells, and antiangiogenesis activities in tube formation and microvessel formation from aortic rings. Moreover, the tissue concentration of sorafenib and curcumin in gastrointestinal tract and major organs were significantly improved after their coassembly into SCN. In particular, in BEL-7402 cells induced tumor xenograft, SCN treatment displayed the obviously enhanced inhibitory effect on tumor progression over free drug monotherapy or their physical mixture, with significantly increased antiproliferation and antiangiogenesis capability. Thereby, the codelivered nanoassemblies of sorafenib and curcumin provided a promising strategy to enhance the combinational therapy of HCC. |
| WOS关键词 | BREAST-CANCER ; MULTIDRUG-RESISTANCE ; ORAL DELIVERY ; TUMOR-GROWTH ; CO-DELIVERY ; COMBINATION ; DOXORUBICIN ; METASTASIS ; INHIBITION ; PACLITAXEL |
| 资助项目 | National Basic Research Program of China[2015CB932103] ; National Basic Research Program of China[2012CB932502] ; National Natural Science Foundation of China[81270047] ; National Natural Science Foundation of China[81373359] |
| WOS研究方向 | Research & Experimental Medicine ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000350390900025 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276624]  |
| 专题 | 药物制剂研究中心 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Zhang, Zhiwen |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China; 3.Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China |
| 推荐引用方式 GB/T 7714 | Cao, Haiqiang,Wang, Yixin,He, Xinyu,et al. Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma[J]. MOLECULAR PHARMACEUTICS,2015,12(3):922-931. |
| APA | Cao, Haiqiang.,Wang, Yixin.,He, Xinyu.,Zhang, Zhiwen.,Yin, Qi.,...&Li, Yaping.(2015).Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma.MOLECULAR PHARMACEUTICS,12(3),922-931. |
| MLA | Cao, Haiqiang,et al."Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma".MOLECULAR PHARMACEUTICS 12.3(2015):922-931. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。